Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | CD38 | P28907 | 7/20 | 0.42 |
| ▸ | STAT3 | P40763 | 3/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786825 | 0.82 | CD38 (0.36) | CD38 | |
| SCHEMBL3780112 | 0.74 | HRH4 (0.51) | GDA | |
| SCHEMBL3799224 | 0.74 | XDH (0.44) | CD38 | |
| SCHEMBL887125 | 0.74 | GDA (0.55) | GDASTAT3NEK2BRAFSRC | |
| SCHEMBL750335 | 0.74 | GDA (0.55) | GDASTAT3NEK2BRAFSRC | |
| SCHEMBL31506448 | 0.74 | GDA (0.55) | GDASTAT3NEK2BRAFSRC | |
| SCHEMBL14938904 | 0.72 | GDA (0.54) | GDANEK2BRAFSRC | |
| SCHEMBL5197101 | 0.72 | GDA (0.54) | GDASTAT3NEK2BRAFSRC | |
| SCHEMBL3768069 | 0.69 | HTT (0.51) | CHEK1 | |
| SCHEMBL4945758 | 0.69 | GDA (0.50) | GDASTAT3NEK2BRAFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101257797-B | Methods for selective N-9 glycosylation of purines | UNIV BRIGHAM YOUNG | 2013-06-12 | — | — | CN | disclosed |
| US-7855285-B2 | Methods for selective N-9 glycosylation of purines | BRIGHAM YOUNG UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| CN-101257797-A | Methods for selective N-9 glycosylation of purines | UNIV BRIGHAM YOUNG (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | BRIGHAM YOUNG UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | PNP, SLC29A2, SLC28A2 | GDA 166/4885CD38 114/4885STAT3 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.